ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

Junjian Wang, June X Zou, Xiaoqian Xue, Demin Cai, Yan Zhang, Zhijian Duan, Qiuping Xiang, Joy C. Yang, Maggie C. Louie, Alexander D Borowsky, Allen C Gao, Christopher P Evans, Kit Lam, Jianzhen Xu, Hsing-Jien Kung, Ronald M. Evans, Yong Xu, Hongwu Chen

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.

Original languageEnglish (US)
Pages (from-to)488-496
Number of pages9
JournalNature Medicine
Volume22
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Tumors
Therapeutics
Genes
Nuclear Receptor Coactivator 3
Neoplasms
Nuclear Receptor Coactivator 1
Retinoic Acid Receptors
Gene Regulatory Networks
Response Elements
Transcription
Tumor Cell Line
Heterografts
Toxicity
Cells
Genome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. / Wang, Junjian; Zou, June X; Xue, Xiaoqian; Cai, Demin; Zhang, Yan; Duan, Zhijian; Xiang, Qiuping; Yang, Joy C.; Louie, Maggie C.; Borowsky, Alexander D; Gao, Allen C; Evans, Christopher P; Lam, Kit; Xu, Jianzhen; Kung, Hsing-Jien; Evans, Ronald M.; Xu, Yong; Chen, Hongwu.

In: Nature Medicine, Vol. 22, No. 5, 01.05.2016, p. 488-496.

Research output: Contribution to journalArticle

Wang, Junjian ; Zou, June X ; Xue, Xiaoqian ; Cai, Demin ; Zhang, Yan ; Duan, Zhijian ; Xiang, Qiuping ; Yang, Joy C. ; Louie, Maggie C. ; Borowsky, Alexander D ; Gao, Allen C ; Evans, Christopher P ; Lam, Kit ; Xu, Jianzhen ; Kung, Hsing-Jien ; Evans, Ronald M. ; Xu, Yong ; Chen, Hongwu. / ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. In: Nature Medicine. 2016 ; Vol. 22, No. 5. pp. 488-496.
@article{f8ddacdabd32498a8acac9835c53dda8,
title = "ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer",
abstract = "The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.",
author = "Junjian Wang and Zou, {June X} and Xiaoqian Xue and Demin Cai and Yan Zhang and Zhijian Duan and Qiuping Xiang and Yang, {Joy C.} and Louie, {Maggie C.} and Borowsky, {Alexander D} and Gao, {Allen C} and Evans, {Christopher P} and Kit Lam and Jianzhen Xu and Hsing-Jien Kung and Evans, {Ronald M.} and Yong Xu and Hongwu Chen",
year = "2016",
month = "5",
day = "1",
doi = "10.1038/nm.4070",
language = "English (US)",
volume = "22",
pages = "488--496",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

AU - Wang, Junjian

AU - Zou, June X

AU - Xue, Xiaoqian

AU - Cai, Demin

AU - Zhang, Yan

AU - Duan, Zhijian

AU - Xiang, Qiuping

AU - Yang, Joy C.

AU - Louie, Maggie C.

AU - Borowsky, Alexander D

AU - Gao, Allen C

AU - Evans, Christopher P

AU - Lam, Kit

AU - Xu, Jianzhen

AU - Kung, Hsing-Jien

AU - Evans, Ronald M.

AU - Xu, Yong

AU - Chen, Hongwu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.

AB - The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.

UR - http://www.scopus.com/inward/record.url?scp=84961878425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961878425&partnerID=8YFLogxK

U2 - 10.1038/nm.4070

DO - 10.1038/nm.4070

M3 - Article

C2 - 27019329

AN - SCOPUS:84961878425

VL - 22

SP - 488

EP - 496

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -